Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stratec SESRBZF 67 Return-on-Tangible-Asset is -2.20% as of Mar. 2026. GuruFocus rates SRBZF with a GF Score™ of 67/100 and a GF Value™ of $120.28. The stock has 5 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Stratec SE ranks worse than 53.4% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Stratec SE's annualizedNet Income for the quarter that ended in Mar. 2026 was $-7.9 Mil. Stratec SE's average total tangible assets for the quarter that ended in Mar. 2026 was $359.7 Mil. Therefore, Stratec SE's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -2.20%.
The historical rank and industry rank for Stratec SE's Return-on-Tangible-Asset or its related term are showing as below:
SRBZF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -1.09 Med: 8.88 Max: 17.54
Current: -1.09
During the past 13 years, Stratec SE's highest Return-on-Tangible-Asset was 17.54%. The lowest was -1.09%. And the median was 8.88%.
SRBZF's Return-on-Tangible-Asset is ranked worse than 53.4% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.665
vs SRBZF: -1.09
Stratec SE (OTCPK:SRBZF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Stratec SE Return-on-Tangible-Asset Related Terms
Stratec SE Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Stratec SE's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SRBZF vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Stratec SE's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stratec SE Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stratec SE's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Stratec SE's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -2.20% mean?
Stratec SE (SRBZF) has a Return-on-Tangible-Asset of -2.20% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Stratec SE and its competitors. According to the industry distribution chart, Stratec SE ranks #456 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 53.4%.
Is Stratec SE's Return-on-Tangible-Asset too high?
Stratec SE's current Return-on-Tangible-Asset is -2.20%. Based on the distribution chart, Stratec SE ranks #456 out of 854 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Stratec SE has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Stratec SE's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Stratec SE ranks #456 out of 854 companies for Return-on-Tangible-Asset. This places Stratec SE in the lower half of its industry. The industry median Return-on-Tangible-Asset is 0.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.67, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Stratec SE and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stratec SE's current Return-on-Tangible-Asset is -2.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stratec SE stock overvalued right now?
Stratec SE (SRBZF) has a current Return-on-Tangible-Asset of -2.20%. The stock's GF Value™ is $120.28, compared to a current price of $72.96 — trading 39.3% below its estimated fair value. The current Return-on-Tangible-Asset is -2.20%. Stratec SE's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Stratec SE (SRBZF), the current Return-on-Tangible-Asset is -2.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stratec SE (SRBZF) Overvalued in 2026?
Based on GuruFocus' analysis, Stratec SE stock appears to be undervalued.
The current stock price of $72.96 is trading 39.3% below its estimated GF Value™ of $120.28.
Key valuation signals for SRBZF:
Return-on-Tangible-Asset: -2.20%
GF Value™: $120.28 vs. price of $72.96 (39.3% below fair value)
No single metric tells the full story. See the SRBZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stratec SE designs and manufactures automation solutions for regulated laboratory markets. STRATEC acts as an OEM partner to players in the in-vitro diagnostics and life sciences markets. The Group's product range includes both hardware solutions, software solutions, and related consumables, as well as independently marketed consumables. These products are mostly combined into fully integrated system solutions and often receive market approval together with partners' reagents.
67GF Score
Get the complete analysis for SRBZF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRBZF has been successfully added to your 
